Harvard Bioscience HBIO Insider Ownership

Updated Oct 10, 2026

Over the trailing 12 months, HBIO insiders bought $202,354 worth of shares in open-market trades, with no open-market sales.

• Counted by insider, open-market buying of HBIO stock in the past 12 months came from 4 insiders, with no insider selling.
• Among HBIO insiders, William Snider (Director) bought the most stock on the open market in the past 12 months: $103,604, most recently on March 17, 2026.
• Harvard Bioscience's latest insider trade on the open market was a purchase of 10K shares for $48,700 by Stephen J. Denelsky (Director) on March 17, 2026.
• Per Business Quant data, Harvard Bioscience insiders hold 688.55K shares in total based on their latest Form 4 filings, unchanged from 688.55K shares at the end of Q2 2026 and up 34.65% from 511.35K shares (split-adjusted) at the end of Q3 2025.
• All of the 688.55K shares held by Harvard Bioscience insiders are held directly, none through trusts, partnerships or other entities.
• Holdings in Harvard Bioscience stock are reported by 9 insiders, the officers, directors and 10% owners who have filed a Form 4 in the past two years.
• HBIO's largest insider holders by reported holdings are James W. Green (Director, 245.26K shares), John D. Duke (Chief Executive Officer, 180K shares) and Katherine A. Eade (Director, 58.67K shares).
• The holding of James W. Green makes up 35.62% of all shares held by Harvard Bioscience insiders.
• Institutional investors held 36.89% of Harvard Bioscience stock at the end of Q2 2026, while the latest Form 4 filings of its insiders account for about 15.13%; other investors, including the public, hold roughly 47.98%.
• Over the past 12 months, 7 insiders reported transactions in Harvard Bioscience stock in 12 Form 4 filings.
• This summary of Harvard Bioscience insider activity covers Form 4 filings through June 12, 2026.